Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 37

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

A Pilot Randomized Clinical Trial of Intranasal Oxytocin to Promote Weight Loss in Individuals With Hypothalamic Obesity

McCormack, Shana E, Wang, Zi, Wade, Kristin L, Dedio, Anna, Cilenti, Nicolette, Crowley, Julia, Plessow, Franziska, Bamba, Vaneeta, Roizen, Jeffrey D, Jiang, Yaoguang, Stylli, Jack, Ramakrishnan, Arjun, Platt, Michael L, Shekdar, Karuna, Fisher, Michael J, Vetter, Victoria L, Hocking, Matthew, Xiao, Rui, Lawson, Elizabeth A·2023·Journal of the Endocrine Society

Abstract

Context: Hypothalamic obesity is a rare, treatment-resistant form of obesity. In preliminary studies, the hypothalamic hormone oxytocin (OXT) has shown promise as a potential weight loss therapy. Objective: To determine whether 8 weeks of intranasal OXT (vs 8 weeks of placebo) promotes weight loss in children, adolescents, and young adults with hypothalamic obesity. Methods: This randomized, double-blind, placebo-controlled, crossover pilot trial (NCT02849743), conducted at an outpatient academic medical center, included patients aged 10 to 35 years with hypothalamic obesity from hypothalamic/pituitary tumors. Participants received intranasal OXT (Syntocinon, 40 USP units/mL, 4 IU/spray) vs excipient-matched placebo, 16 to 24 IU 3 times daily at mealtimes. Weight loss attributable to OXT vs placebo and safety (adverse events) were assessed. Results: Of 13 individuals randomized (54% female, 31% pre-pubertal, median age 15.3 years, IQR 13.3-20.6), 10 completed the entire study. We observed a nonsignificant within-subject weight change of −0.6 kg (95% CI: −2.7, 1.5) attributable to OXT vs placebo. A subset (2/18 screened, 5/13 randomized) had prolonged QTc interval on electrocardiography prior to screening and/or in both treatment conditions. Overall, OXT was well-tolerated, and adverse events (epistaxis and nasal irritation, headache, nausea/vomiting, and changes in heart rate, blood pressure, and QTc interval) were similar between OXT and placebo. In exploratory analyses, benefits of OXT for anxiety and impulsivity were observed. Conclusion: In this pilot study in hypothalamic obesity, we did not detect a significant impact of intranasal OXT on body weight. OXT was well-tolerated, so future larger studies could examine different dosing, combination therapies, and potential psychosocial benefits.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jendso/bvad037

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 53

  1. Muller, 2020, Management of hypothalamic obesity, Endocrinol Metab Clin North Am, 49, 533, 10.1016/j.ecl.2020.05.009 · DOI
  2. Madsen, 2019, Endoscopic endonasal resection versus open surgery for pediatric craniopharyngioma: comparison of outcomes and complications, J Neurosurg Pediatr, 24, 236, 10.3171/2019.4.PEDS18612 · DOI
  3. Shaikh, 2008, Reductions in basal metabolic rate and physical activity contribute to hypothalamic obesity, J Clin Endocrinol Metab, 93, 2588, 10.1210/jc.2007-2672 · DOI
  4. Cohen, 2013, Autonomic nervous system balance in children and adolescents with craniopharyngioma and hypothalamic obesity, Eur J Endocrinol, 168, 845, 10.1530/EJE-12-1082 · DOI
  5. Roth, 1998, Hyperphagia in children with craniopharyngioma is associated with hyperleptinaemia and a failure in the downregulation of appetite, Eur J Endocrinol, 138, 89, 10.1530/eje.0.1380089 · DOI · Paper page
  6. Olsson, 2015, Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden, J Clin Endocrinol Metab, 100, 467, 10.1210/jc.2014-3525 · DOI · Paper page
  7. Jung, 2017, Nonalcoholic fatty liver disease in long-term survivors of childhood-onset craniopharyngioma, Ann Pediatr Endocrinol Metab, 22, 189, 10.6065/apem.2017.22.3.189 · DOI
  8. Yuen, 2018, Relative risks of contributing factors to morbidity and mortality in adults with craniopharyngioma on growth hormone replacement, J Clin Endocrinol Metab, 103, 768, 10.1210/jc.2017-01542 · DOI
  9. Qiao, 2019, Excess mortality after craniopharyngioma treatment: are we making progress?, Endocrine, 64, 31, 10.1007/s12020-018-1830-y · DOI
  10. Rose, 2018, Hypothalamic obesity: 4 years of the international registry of hypothalamic obesity disorders, Obesity (Silver Spring), 26, 1727, 10.1002/oby.22315 · DOI
  11. van Iersel, 2019, Pathophysiology and individualized treatment of hypothalamic obesity following craniopharyngioma and other suprasellar tumors: a systematic review, Endocr Rev, 40, 193, 10.1210/er.2018-00017 · DOI · Paper page
  12. McCormack, 2020, Metabolic effects of oxytocin, Endocr Rev, 41, 121, 10.1210/endrev/bnz012 · DOI
  13. Daubenbuchel, 2016, Oxytocin in survivors of childhood-onset craniopharyngioma, Endocrine, 54, 524, 10.1007/s12020-016-1084-5 · DOI · Paper page
  14. Hsu, 2018, Oxytocin and naltrexone successfully treat hypothalamic obesity in a boy post-craniopharyngioma resection, J Clin Endocrinol Metab, 103, 370, 10.1210/jc.2017-02080 · DOI
  15. Lustig, 2003, Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial, J Clin Endocrinol Metab, 88, 2586, 10.1210/jc.2002-030003 · DOI · Paper page
  16. Liu, 2020, Sex differences and estrous influences on oxytocin control of food intake, Neuroscience, 447, 63, 10.1016/j.neuroscience.2019.10.020 · DOI
  17. Blevins, 2015, Chronic oxytocin administration inhibits food intake, increases energy expenditure, and produces weight loss in fructose-fed obese rhesus monkeys, Am J Physiol Regul Integr Comp Physiol, 308, R431, 10.1152/ajpregu.00441.2014 · DOI · Paper page
  18. Kuczmarski, 2000, CDC Growth charts: United States, Adv Data, 1
  19. Plessow, 2021, Oxytocin administration increases proactive control in men with overweight or obesity: a randomized, double-blind, placebo-controlled crossover study, Obesity (Silver Spring), 29, 56, 10.1002/oby.23010 · DOI
  20. Bartholdy, 2016, A systematic review of the relationship between eating, weight and inhibitory control using the stop signal task, Neurosci Biobehav Rev, 64, 35, 10.1016/j.neubiorev.2016.02.010 · DOI · Paper page
  21. Logan, 2014, On the ability to inhibit thought and action: general and special theories of an act of control, Psychol Rev, 121, 66, 10.1037/a0035230 · DOI · Paper page
  22. Dykens, 2007, Assessment of hyperphagia in Prader-Willi syndrome, Obesity (Silver Spring, Md), 15, 1816, 10.1038/oby.2007.216 · DOI · Paper page
  23. Stunkard, 1985, The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger, J Psychosom Res, 29, 71, 10.1016/0022-3999(85)90010-8 · DOI · Paper page
  24. Zemel, 2010, Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children, J Clin Endocrinol Metab, 95, 1265, 10.1210/jc.2009-2057 · DOI · Paper page
  25. Epstein, 1983, The McMaster family assessment device, J Marital Family Therapy, 9, 171, 10.1111/j.1752-0606.1983.tb01497.x · DOI · Paper page
  26. Greenhill, 2004, Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology, J Am Acad Child Adolesc Psychiatry, 43, 1488, 10.1097/01.chi.0000142668.29191.13 · DOI
  27. Hocking, 2015, Family functioning mediates the association between neurocognitive functioning and health-related quality of life in young adult survivors of childhood brain tumors, J Adolesc Young Adult Oncol, 4, 18, 10.1089/jayao.2014.0022 · DOI
  28. Mong, 2008, Cardiac risk after craniopharyngioma therapy, Pediatric Neurol, 38, 256, 10.1016/j.pediatrneurol.2007.11.007 · DOI · Paper page
  29. Muller, 2011, Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up, Eur J Endocrinol, 165, 17, 10.1530/EJE-11-0158 · DOI · Paper page
  30. Anekonda, 2021, Hindbrain administration of oxytocin reduces food intake, weight gain and activates catecholamine neurons in the hindbrain nucleus of the solitary tract in rats, J Clin Med, 10, 5078, 10.3390/jcm10215078 · DOI
  31. Alaerts, 2021, Changes in endogenous oxytocin levels after intranasal oxytocin treatment in adult men with autism: an exploratory study with long-term follow-up, Eur Neuropsychopharmacol, 43, 147, 10.1016/j.euroneuro.2020.11.014 · DOI
  32. Blevins, 2015, Translational and therapeutic potential of oxytocin as an anti-obesity strategy: insights from rodents, nonhuman primates and humans, Physiol Behav, 152, 438, 10.1016/j.physbeh.2015.05.023 · DOI
  33. Kou, 2021, In the nose or on the tongue? Contrasting motivational effects of oral and intranasal oxytocin on arousal and reward during social processing, Transl Psychiatry, 11, 94, 10.1038/s41398-021-01241-w · DOI
  34. Lee, 2018, Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay, Mol Psychiatry, 23, 115, 10.1038/mp.2017.27 · DOI · Paper page
  35. Ishii, 2021, Cerebral and extracerebral distribution of radioactivity associated with oxytocin in rabbits after intranasal administration: comparison of TTA-121, a newly developed oxytocin formulation, with syntocinon, PloS one, 16, 10.1371/journal.pone.0261451 · DOI
  36. Dykens, 2018, Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome, JCI Insight, 3, 10.1172/jci.insight.98333 · DOI
  37. Vankrieken, 1983, Oxytocin determination by radioimmunoassay, Gynecol Obstet Invest, 16, 180, 10.1159/000299248 · DOI
  38. Geschwind, 2021, Oxytocin for autism spectrum disorder - down, but not out, N Engl J Med, 385, 1524, 10.1056/NEJMe2110158 · DOI
  39. Damen, 2021, Oxytocin in young children with Prader-Willi syndrome: results of a randomized, double-blind, placebo-controlled, crossover trial investigating 3 months of oxytocin, Clin Endocrinol (Oxf), 94, 774, 10.1111/cen.14387 · DOI
  40. Hollander, 2021, Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi syndrome: a randomized controlled pilot trial, J Psychiatr Res, 137, 643, 10.1016/j.jpsychires.2020.11.006 · DOI
  41. Hoffmann, 2015, Eating behavior, weight problems and eating disorders in 101 long-term survivors of childhood-onset craniopharyngioma, J Pediatr Endocrinol Metab, 28, 35, 10.1515/jpem-2014-0415 · DOI
  42. Bishop-Gilyard, 2011, Weight reduction in obese adolescents with and without binge eating, Obesity (Silver Spring), 19, 982, 10.1038/oby.2010.249 · DOI
  43. Daughters, 2017, Hypopituitarism is associated with lower oxytocin concentrations and reduced empathic ability, Endocrine, 57, 166, 10.1007/s12020-017-1332-3 · DOI
  44. Aulinas, 2019, Low plasma oxytocin levels and increased psychopathology in hypopituitary men with diabetes insipidus, J Clin Endocrinol Metab, 104, 3181, 10.1210/jc.2018-02608 · DOI
  45. Eisenberg, 2019, Oxytocin alterations and neurocognitive domains in patients with hypopituitarism, Pituitary, 22, 105, 10.1007/s11102-019-00936-0 · DOI
  46. Hoffmann, 2017, First experiences with neuropsychological effects of oxytocin administration in childhood-onset craniopharyngioma, Endocrine, 56, 175, 10.1007/s12020-017-1257-x · DOI · Paper page
  47. Roth, 2021, A phase 3 randomized clinical trial using once-weekly GLP-1 receptor agonist in adolescents and young adults with hypothalamic obesity, Diabetes Obes Metab, 23, 363, 10.1111/dom.14224 · DOI · Paper page
  48. Altszuler, 1981, Intranasal instillation of oxytocin increases insulin and glucagon secretion, Proc Soc Exp Biol Med, 168, 123, 10.3181/00379727-168-41245 · DOI · Paper page
  49. Chiodera, 1984, Effect of pharmacological doses of oxytocin on insulin response to glucose in normal man, Hormone Res, 20, 150, 10.1159/000179988 · DOI
  50. Brede, 2019, Intranasal oxytocin fails to acutely improve glucose metabolism in obese men, Diabetes Obes Metab, 21, 424, 10.1111/dom.13527 · DOI
  51. Acosta, 2021, Selection of antiobesity medications based on phenotypes enhances weight loss: a pragmatic trial in an obesity clinic, Obesity (Silver Spring), 29, 662, 10.1002/oby.23120 · DOI · Paper page
  52. Edwards, 2021, Effects of combined oxytocin and beta-3 receptor agonist (CL 316243) treatment on body weight and adiposity in male diet-induced obese rats, Front Physiol, 12, 10.3389/fphys.2021.725912 · DOI
  53. Kakouri, 2021, New incretin combination treatments under investigation in obesity and metabolism: a systematic review, Pharmaceuticals (Basel), 14, 869, 10.3390/ph14090869 · DOI

Cited by

See all 37

Metadata

Authors
McCormack, S. E., Wang, Z., Wade, K. L., Dedio, A., Cilenti, N., Crowley, J., Plessow, F., Bamba, V., Roizen, J. D., Jiang, Y., Stylli, J., Ramakrishnan, A., Platt, M. L., Shekdar, K., Fisher, M. J., Vetter, V. L., Hocking, M., Xiao, R., & Lawson, E. A.
Affiliations
  • Division of Endocrinology & Diabetes, Children's Hospital of Philadelphia , Philadelphia, PA 19104 , USA
  • Biostatistics & Data Management, Children's Hospital of Philadelphia , Philadelphia, PA 19104 , USA
  • Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School , Boston, MA 02114 , USA
  • Department of Psychology, School of Arts and Sciences, University of Pennsylvania , Philadelphia, PA 19104 , USA
  • Georgetown University School of Medicine , Washington, DC 20007 , USA
  • Department of Biological Sciences and Bioengineering, Indian Institute of Technology , Kanpur, Uttar Pradesh 208016 , India
  • Division of Neuroradiology, Children's Hospital of Philadelphia , Philadelphia, PA 19104 , USA
  • Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania , Philadelphia, PA 19104 , USA
  • Center for Childhood Cancer Research and Division of Oncology, Children's Hospital of Philadelphia , Philadelphia, PA 19104 , USA
  • Center of Clinical Epidemiology & Biostatistics, Perelman School of Medicine at the University of Pennsylvania , Philadelphia, PA 19104 , USA
Venue
Journal of the Endocrine Society
Published
2023-03-06
Volume
7
Issue
5
ISSN
2472-1972
Cited by
37
References
22
Language
en
Funders
Doris Duke Clinical Scientist Development Award

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Pilot Randomized Clinical Trial of Intranasal Oxytocin to Promote Weight Loss in Individuals With Hypothalamic Obesity. https://app.cochat.ai/papers/10.1210/jendso/bvad037
The paper
McCormack, S. E., Wang, Z., Wade, K. L., Dedio, A., Cilenti, N., Crowley, J., Plessow, F., Bamba, V., Roizen, J. D., Jiang, Y., Stylli, J., Ramakrishnan, A., Platt, M. L., Shekdar, K., Fisher, M. J., Vetter, V. L., Hocking, M., Xiao, R., & Lawson, E. A. (2023). A Pilot Randomized Clinical Trial of Intranasal Oxytocin to Promote Weight Loss in Individuals With Hypothalamic Obesity. Journal of the Endocrine Society. https://doi.org/10.1210/jendso/bvad037

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.